Skip to main content

Pfizer

Lupus Nephritis Market to Reach $4.08B by 2034, 8.5% CAGR

Lupus Nephritis Market to Reach $4.08B by 2034, 8.5% CAGR

Pune, India – September 22, 2026 -- The global lupus nephritis market was valued at $1.96 billion in 2025 and is projected to reach $4.08 billion by 2034, expanding at a compound annual growth rate of 8.5% through the forecast period, according to a new analysis by Maximize Market Research.

North America leads treatment adoption on strong pharmaceutical research capabilities

North America holds the leading position in the market, supported by advanced healthcare infrastructure and higher awareness of autoimmune diseases. The United States drives regional demand through its established pharmaceutical industry and strong clinical research activity, while Canada contributes through its developed healthcare system focused on autoimmune disease management.

NCCN, Pfizer Fund Four Quality Projects to Close mPCA Care Gaps

NCCN, Pfizer Fund Four Quality Projects to Close mPCA Care Gaps

Plymouth Meeting, Pa. – September 17, 2026 -- The National Comprehensive Cancer Network (NCCN) Oncology Research Program has awarded funding for four quality improvement projects targeting metastatic prostate cancer (mPCA) care, backed by Pfizer Global Medical Grants (GMG).

Four institutions receive two-year grants to standardize mPCA treatment protocols

The selected projects, each set for completion within two years, will run at UT Southwestern Simmons Comprehensive Cancer Center, Georgetown University, Northwestern University's Robert H. Lurie Comprehensive Cancer Center, and Moffitt Cancer Center. Changchuan (Charles) Jiang, MD, at UT Southwestern will lead a biomarker action-loop initiative within a major U.S. safety-net cancer program. Paul Leger, MD, at Georgetown will implement multilevel interventions across the Medstar Health Network under the I-CARE PCA project.